a Department of Pediatrics , Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, College of Medicine , Kaohsiung , Taiwan.
b Institute for Translational Research in Biomedicine , Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, College of Medicine , Kaohsiung , Taiwan.
Clin Exp Hypertens. 2018;40(1):58-64. doi: 10.1080/10641963.2017.1313847. Epub 2017 Oct 26.
ABSTACT Hydrogen sulfide (HS), nitric oxide (NO), and renin-angiotensin system (RAS) are involved in hypertension. We examined whether early treatment with sodium hydrosulfide (NaHS), an exogenous HS donor, can regulate HS-generating pathway, NO pathway, and the RAS, to prevent the transition from prehypertension to hypertension in spontaneously hypertensive rats (SHRs). Four-week-old SHRs and control normotensive Wistar-Kyoto (WKY) rats were assigned into three groups: WKY, SHRs, and SHR + NaHS; SHRs were injected intraperitoneally with sodium hydrosulfide (14 μmol/kg/day) for 4 weeks. SHRs exhibited hypertension at 12 weeks of age, which was blocked by early sodium hydrosulfide administration. Concentrations of HS were increased in the kidney in SHR + NaHS group versus WKY. Sodium hydrosulfide reduces mRNA expression of four HS-generating enzymes and decreased 3-mercaptopyruvate sulphurtransferase protein level in SHRs. Early administration of sodium hydrosulfide decreases plasma N monomethyl-l-arginine (l-NMMA, an inhibitor of NO synthase) level and increases plasma NO level in SHRs. Next, sodium hydrosulfide administration reduces renal mRNA expression of Ren, Atp6ap2, Agt, Ace, and Agtr1a in SHRs. We conclude that early short-term sodium hydrosulfide treatment increases renal HS concentrations, restores NO bioavailability, and blocks the RAS in the kidney, in favor of vasodilatation to prevent the development of hypertension in adult SHRs.
摘要 硫化氢 (HS)、一氧化氮 (NO) 和肾素-血管紧张素系统 (RAS) 参与高血压的发生。本研究旨在探讨外源性 HS 供体硫氢化钠 (NaHS) 早期治疗能否调节 HS 生成途径、NO 途径和 RAS,从而防止自发性高血压大鼠 (SHR) 从高血压前期发展为高血压。4 周龄 SHR 和对照正常血压 Wistar-Kyoto (WKY) 大鼠分为三组:WKY、SHR 和 SHR+NaHS;SHR 经腹腔注射 NaHS (14 μmol/kg/天) 治疗 4 周。12 周龄时 SHR 出现高血压,早期给予 NaHS 可阻断其发展。与 WKY 相比,SHR+NaHS 组肾脏中 HS 浓度增加。NaHS 降低了 SHR 中四种 HS 生成酶的 mRNA 表达水平,降低了 3-巯基丙酮酸硫转移酶蛋白水平。早期给予 NaHS 可降低 SHR 血浆 N 单甲基-L-精氨酸 (l-NMMA,一种 NO 合酶抑制剂) 水平,增加血浆 NO 水平。此外,NaHS 给药降低了 SHR 肾脏中 Ren、Atp6ap2、Agt、Ace 和 Agtr1a 的 mRNA 表达。综上,短期早期 NaHS 治疗可增加肾脏 HS 浓度,恢复 NO 生物利用度,阻断肾脏 RAS,有利于血管舒张,从而防止成年 SHR 发生高血压。